港股異動 | 兆科眼科(6622.HK)上市首日大跌14.4% 每手浮虧1210港元
格隆匯4月29日丨身處黃金賽道的兆科眼科,雖然有高瓴、正心谷、愛爾眼科等基石股東為其“站台”,但是該股的光環在上市首日湮滅。兆科眼科(6622.HK)今日低開約7.6%,隨後快速走低,現跌幅擴大至14.4%,報14.38港元,總市值77億港元。不計手續費,每手浮虧1210港元。公司是由李氏大藥廠分拆上市,全球發售約1.236億股,其中香港發售4942.7萬股,國際發售7414.05萬股,每手500股,一手中籤率25%,香港公開發售獲56倍認購,淨籌19.416億港元。招股書顯示,本次IPO款項用途,所有款項淨額的32%將用於兆科眼科核心產品(環孢素A和ZKY001)的臨牀開發及商業化,46%將用於其它在研候選藥物的持續研發以及商業化,7%將用於生產線擴張,15%將用於業務運營及其他一般企業用途。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.